ChiCTR2500097198 版本V1.0 版本创建时间2025/02/14 09:28:17 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500097198 

最近更新日期:

Date of Last Refreshed on:

2025-02-14 09:26:34 

注册时间:

Date of Registration:

2025-02-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

甘氨酸改善胆固醇代谢的作用及机制研究

Public title:

The mechanisms of cholesterol lowering effects of glycine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

甘氨酸改善胆固醇代谢的作用及机制研究

Scientific title:

The mechanisms of cholesterol lowering effects of glycine

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王一然 

研究负责人:

冯任南 

Applicant:

Wang Yiran 

Study leader:

Feng Rennan 

申请注册联系人电话:

Applicant telephone:

+86 150 4586 8262

研究负责人电话:

Study leader's
telephone:

+86 159 4566 7279

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yiranwang@hrbmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

fengrennan@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

黑龙江省哈尔滨市南岗区保健路157号

研究负责人通讯地址:

黑龙江省哈尔滨市南岗区保健路157号

Applicant address:

157 Nangang District, Harbin health care road, Harbin

Study leader's address:

157 Nangang District, Harbin health care road, Harbin

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

哈尔滨医科大学

Applicant's institution:

Harbin Medical University

研究负责人所在单位:

哈尔滨医科大学

Affiliation of the Leader:

Harbin Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

HMUIRB2024032PRE

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

哈尔滨医科大学伦理委员会

Name of the ethic committee:

Institutional Review Board of Harbin Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-17 00:00:00

伦理委员会联系人:

吴雪松

Contact Name of the ethic committee:

Wu Xuesong

伦理委员会联系地址:

黑龙江省哈尔滨市南岗区保健路157号哈尔滨医科大学

Contact Address of the ethic committee:

Harbin Medical University, 157 Baojian Road, Nangang District, Harbin, Heilongjiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 138 3603 8306

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

哈尔滨医科大学

Primary sponsor:

Harbin Medical University

研究实施负责(组长)单位地址:

黑龙江省哈尔滨市南岗区保健路157号

Primary sponsor's address:

157 Nangang District, Harbin health care road, Harbin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

黑龙江

市(区县):

Country:

China

Province:

Heilongjiang

City:

单位(医院):

哈尔滨医科大学

具体地址:

黑龙江省哈尔滨市南岗区保健路157号

Institution
hospital:

Harbin Medical University

Address:

157 Nangang District, Harbin health care road, Harbin

经费或物资来源:

国家自然科学基金

Source(s) of funding:

National Natural Science Foundation of China (NSFC)

研究疾病:

高脂血症  

Target disease:

Hyperlipemia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探究甘氨酸补充4个月对高脂血症的作用  

Objectives of Study:

To investigate whether glycine supplementation for 4 months could improve hyperlipemia and related metabolic disordes.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄30~65岁; 2.高脂血症,包括边缘高脂血症,TC≥5.17 mmol/L和/或TG≥2.26 mmol/L; 3.自愿参加,已经签署知情同意书;

Inclusion criteria

1. Age 30-65 years old; 2. Hyperlipidemia, including borderline hyperlipidemia, TC>=5.17 mmol/L and/or TG>=2.26 mmol/L; 3. Voluntary participation and signed informed consent.

排除标准:

1.酒精摄入过量(> 70 g/week); 2.过敏史严重人群; 3.吸烟; 4.病毒性肝炎、HIV等传染病的患者; 5.孕期、哺乳期或处于绝经期边缘人群; 6.肿瘤; 7.肾功不全; 8.糖尿病; 9.正在减重或体重近期发生波动; 10.服用激素类药物; 11.居住环境、生活饮食习惯不稳定的人群。

Exclusion criteria:

1. Excessive alcohol intake (> 70 g/week); 2. People with severe allergic history; 3. Smoking; 4. Patients with viral hepatitis, HIV and other infectious diseases; 5. Pregnant, lactating or on the verge of menopause; 6. Tumor; 7. Renal insufficiency; 8. Diabetes; 9. Losing weight or weight has fluctuated recently; 10. Take hormone drugs; 11. Patients with unstable living environment, living and eating habits.

研究实施时间:

Study execute time:

From 2025-02-17 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-02-17 00:00:00 To 2025-03-07 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

35

Group:

Experimental group

Sample size:

干预措施:

甘氨酸

干预措施代码:

Intervention:

Glycine

Intervention code:

组别:

对照组

样本量:

35

Group:

Control group

Sample size:

干预措施:

麦芽糊精

干预措施代码:

Intervention:

maltodextrin

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

黑龙江 

市(区县):

 

Country:

China

Province:

Heilongjiang

City:

单位(医院):

哈尔滨医科大学 

单位级别:

大学 

Institution
hospital:

Harbin Medical University

Level of the institution:

University

测量指标:

Outcomes:

指标中文名:

血胆固醇

指标类型:

主要指标

Outcome:

Cholestrols

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂

指标类型:

主要指标

Outcome:

Blood lipids

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高密度脂蛋白胆固醇

指标类型:

主要指标

Outcome:

High density lipoprotein cholesterol

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白胆固醇

指标类型:

主要指标

Outcome:

Low density lipoprotein cholesterol

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谷草转氨酶

指标类型:

次要指标

Outcome:

Glutamic oxalacetic transaminase

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谷丙转氨酶

指标类型:

次要指标

Outcome:

Glutamic-pyruvic transaminase

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 30 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Table of random numbers

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲,对研究者、患者设盲

Blinding:

Double-blind, blinding the investigator and patient

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

原始数据采用电子表格录入保存,采用Excel数据进行保存

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The original records are in excel format.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-02-14 09:26:34